IFN-γ, IL-17A, IL-4, and IL-13: Potential Biomarkers for Prediction of the Effectiveness of Biologics in Psoriasis Patients.

Biologics are widely used to treat moderate-to-severe psoriasis. However, we have unmet needs for predicting individual patient responses to biologics before starting psoriasis treatment. We investigate a reliable platform and biomarkers for predicting individual patient responses to biologics. In a cohort study between 2018 and 2023 from a referral center in Taiwan, twenty psoriasis patients with or without psoriatic arthritis who had ever experienced two or more biologics were enrolled. Peripheral blood mononuclear cells obtained from these patients were treated with and different biologics. The PASI reduction rate was strongly correlated with the reduction rate in the IL-13 level ( = 0.001) and the ratios of IFN-γ to IL-13 ( < 0.001), IFN-γ to IL-4 ( = 0.019), and IL-17A to IL-13 ( = 0.001). The PASI reduction difference was strongly correlated with the difference in the IFN-γ level ( = 0.002), the difference in the ratios of IFN-γ to IL-4 ( = 0.041), the difference in the ratios of IFN-γ to IL-13 ( = 0.006), the difference in the ratios of IL-17A to IL-4 ( = 0.011), and the difference in the ratios of IL-17A to IL-13 ( = 0.029). The biomarkers IFN-γ, IL-13, IFN-γ/IL4, IFN-γ/IL13, IL-17A/IL-4, and IL-17A/IL-13 are representative of the effectiveness of psoriasis treatment.